Teleflex Incorporated (TFX)
Healthcare
Medical Instruments & Supplies
136.70 $
Closing price · As of: 31. Jul 2026
Who owns Teleflex Incorporated (TFX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.6% of the shares are freely tradable; institutional investors hold 110.9%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
110.9%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
99.6%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
8.0%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
44Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 12.18 | 5,391,991 | +1.0 | 03/31/2026 |
| Vanguard Group Inc | 10.75 | 4,759,015 | -0.8 | 12/31/2025 |
| HHG PLC | 9.69 | 4,291,311 | +1.1 | 03/31/2026 |
| T. Rowe Price Investment Management,Inc. | 8.67 | 3,836,207 | -46.7 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 5.51 | 2,438,183 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.48 | 1,983,824 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Janus Henderson Enterprise D | 6.52 | 2,885,870 | +0.0 | 03/31/2026 |
| Janus Inst Mid Cap Growth CF | 6.52 | 2,885,870 | +0.0 | 03/31/2026 |
| iShares Core S&P Small-Cap ETF | 6.06 | 2,681,238 | +0.0 | 05/29/2026 |
| T. Rowe Price US Mid-Cap Growth Equity | 4.11 | 1,819,500 | -11.5 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.